Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INBS
INBS logo

INBS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.360
Open
2.250
VWAP
2.30
Vol
64.65K
Mkt Cap
5.48M
Low
2.250
Amount
148.69K
EV/EBITDA(TTM)
--
Total Shares
2.39M
EV
-1.69M
EV/OCF(TTM)
--
P/S(TTM)
0.59
Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes.
Show More

Events Timeline

(ET)
2026-06-02
09:10:00
Intelligent Bio Solutions Initiates Multi-Site Study for FDA Submission
select
2026-04-20 (ET)
2026-04-20
09:40:00
Intelligent Bio Solutions Launches Validation Study for Drug Screening System
select
2026-04-17 (ET)
2026-04-17
08:40:00
Intelligent Bio Solutions Completes Penetration Testing, Enhances FDA Submission
select
2026-04-02 (ET)
2026-04-02
09:00:00
Intelligent Bio Solutions Completes Clinical Study Supporting FDA Submission
select
2026-02-25 (ET)
2026-02-25
08:50:00
Intelligent Bio Solutions Ships First Fingerprinting Drug Screening Readers
select
2026-02-24 (ET)
2026-02-24
08:50:00
Intelligent Bio Solutions Partners with Bouygues UK
select
2026-02-12 (ET)
2026-02-12
08:40:00
INBS Reports Q2 Revenue of $896,774, Up 47% Year-Over-Year
select
2026-02-05 (ET)
2026-02-05
08:40:00
Intelligent Bio Solutions Expects Over 100% Sales Growth in Q2
select
2026-01-28 (ET)
2026-01-28
08:40:00
Intelligent Bio Solutions Launches Clinical Study to Support FDA Submission
select
2026-01-09 (ET)
2026-01-09
17:10:00
Intelligent Bio Solutions Files to Sell 6.9M Shares of Common Stock
select

News

NASDAQ.COM
9.0
06-16NASDAQ.COM
Intelligent Bio Solutions Initiates Clinical Study for Drug Screening System
  • Clinical Study Launch: Intelligent Bio Solutions Inc. has announced the initiation of a clinical study to support its 510(k) application for the Fingerprint Drug Screening system, with completion expected by mid-July 2026, aimed at enhancing the accuracy and efficiency of drug screening.
  • Rapid Screening Mechanism: The system utilizes a hygienic fingerprint sweat screening mechanism that can deliver results for opiate drugs like codeine within 10 minutes, addressing workplace needs for quick drug testing and improving corporate safety management capabilities.
  • Collaborative Research: The company has partnered with CenExel Clinical Research Inc. to conduct clinical and interference studies to validate the test's precision in identifying codeine residues, ensuring compliance with FDA's stringent interference testing requirements to reduce false positives.
  • Data Submission Preparation: Results from the study will be included in the FDA 510(k) submission package, along with data from the cut-off study and method comparison study, further enhancing the product's market competitiveness and regulatory compliance.
Newsfilter
8.5
06-16Newsfilter
Intelligent Bio Solutions Initiates Interference Study for Drug Screening System
  • Study Launch: Intelligent Bio Solutions Inc. has announced the initiation of an Interference Study aimed at validating the specificity of its Intelligent Fingerprinting Drug Screening System against common interfering substances in real-world settings, with completion expected by mid-July 2026.
  • Clinical Collaboration: The study will be conducted in partnership with CenExel Clinical Research, enrolling 75 healthy adult participants to assess the accuracy of the test after exposure to potential interferents, thereby ensuring the system's reliability in practical applications.
  • FDA Requirement: Interference testing is a critical FDA requirement that validates whether a diagnostic system can accurately distinguish the target analyte from other substances encountered in daily life, preventing false-positive or false-negative results that could significantly impact workplace drug screening programs.
  • Comprehensive Clinical Package: This study runs concurrently with the Method Comparison Study and the clinical Cut-off Study, forming a comprehensive clinical package designed to meet FDA 510(k) requirements and demonstrate the safety, accuracy, usability, and specificity of the Intelligent Fingerprinting Drug Screening System.
Newsfilter
1.0
06-04Newsfilter
Intelligent Bio Solutions to Participate in Planet MicroCap Conference
  • Conference Participation: Intelligent Bio Solutions Inc. will participate in the Planet MicroCap Conference from June 16-18, 2026, at the Bellagio Hotel in Las Vegas, showcasing its innovative non-invasive testing solutions, which is expected to attract potential investor interest.
  • Presentation Schedule: The management team is set to present on June 17 from 8:00 to 8:30 AM, aiming to highlight the advantages of its Intelligent Fingerprinting Drug Screening System, thereby enhancing market awareness and attracting investments.
  • One-on-One Meetings: Throughout the event, INBS will arrange one-on-one meetings with investors, providing opportunities for in-depth business discussions, which aim to strengthen relationships with potential investors and drive future funding opportunities.
  • Technological Advantage: The Intelligent Fingerprinting Drug Screening System enables rapid and hygienic drug testing through fingerprint sweat analysis, delivering results in under ten minutes, which is expected to provide a crucial tool for employers in safety-critical industries, enhancing industry safety standards.
Newsfilter
8.5
06-02Newsfilter
Initiation of Intelligent Fingerprinting Drug Screening System Study
  • Study Launch: Intelligent Bio Solutions Inc. has announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission, expecting to complete participant enrollment and data collection by the end of July 2026, aimed at validating the accuracy of the Intelligent Fingerprinting Drug Screening System.
  • Participant Recruitment: The study will enroll 135 donor participants randomized into dosing groups, with demographics designed to reflect the diversity of the U.S. population, ensuring the broad applicability and effectiveness of the study results.
  • User Performance Evaluation: The study will assess key performance metrics including the system's sensitivity, specificity, and overall accuracy, with results independently confirmed via liquid chromatography-tandem mass spectrometry (LC-MS/MS), ensuring the reliability and validity of the data.
  • Market Competitive Advantage: The CEO stated that demonstrating typical workplace personnel can accurately operate the system will validate a core competitive advantage, enhancing its market position in workplace drug screening, particularly in the potential for U.S. market expansion.
seekingalpha
9.5
05-13seekingalpha
Intelligent Bio Solutions Reports Q3 Financial Results
  • Financial Highlights: Intelligent Bio Solutions reported a Q3 GAAP EPS of -$1.80, indicating a loss; however, the company showed resilience with improvements in revenue and gross margin.
  • Revenue Growth: The Q3 revenue reached $1.06 million with a gross profit margin of 50.5%, up from 46.8% in the same period last year, reflecting positive progress in cost management and sales strategies.
  • Sales Performance: For the nine months ended March 31, 2026, cartridge sales totaled $1.86 million, a 46% year-over-year increase, representing 61% of total revenue, indicating strong product demand.
  • Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $6.86 million, significantly up from $740,371 at December 31, 2025, enhancing financial stability and future investment capacity.
Newsfilter
9.5
05-13Newsfilter
Intelligent Bio Solutions Reports Strong Q3 Revenue Growth and Margin Expansion
  • Significant Revenue Growth: Q3 cartridge revenue surged 59% year-over-year to $703,538, representing 66% of total quarterly sales, indicating strong performance under the recurring revenue model and expected to drive future market expansion.
  • Robust Nine-Month Performance: Total revenue for the nine months ended March 31, 2026, reached $3.07 million, up 39% year-over-year, building on a $2.01 million first-half milestone, demonstrating sustained commercial momentum.
  • Margin Expansion: The gross margin for Q3 hit 50.5%, up approximately 800 basis points from 46.8% in the prior year, reflecting successful operational efficiencies and increased sales volumes, enhancing unit economics.
  • Market Investment Returns: The company's $1.77 million marketing investment over the past nine months directly contributed to 39% revenue growth, while Q3 marketing spend decreased by 42% year-over-year, indicating improved brand awareness and market presence.

Valuation Metrics

The current forward P/E ratio for Intelligent Bio Solutions Inc (INBS.O) is 0.00, compared to its 5-year average forward P/E of -1.52. For a more detailed relative valuation and DCF analysis to assess Intelligent Bio Solutions Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.52
Current PE
0.00
Overvalued PE
0.83
Undervalued PE
-3.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
16.49
Current PS
0.00
Overvalued PS
52.17
Undervalued PS
-19.18

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

short-term speculative price
Intellectia · 22 candidates
Market Cap: 5.00M - 50.00MRegion: USPrice: $1.00 - $10.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5, PriceCrossAboveMA5One Day Rise Prob: >= 0One Week Rise Prob: >= 0Monthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
CHNR logo
CHNR
China Natural Resources Inc
5.28M
INBS logo
INBS
Intelligent Bio Solutions Inc
5.86M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
6.09M
UCAR logo
UCAR
U Power Ltd
7.55M
RVYL logo
RVYL
Ryvyl Inc
8.74M
BCAB logo
BCAB
Bioatla Inc
9.43M
buyout soon
Intellectia · 22 candidates
Industry: Biotechnology & Medical Research, PharmaceuticalsRegion: USCurrent Ratio: >= 1.20List Exchange: XNYS, XNAS, XASEPs Ratio: <= 4.00Year Price Change Pct: <= $-40.00
Ticker
Name
Market Cap$
top bottom
MBIO logo
MBIO
Mustang Bio Inc
5.30M
ENVB logo
ENVB
Enveric Biosciences Inc
3.71M
LFVN logo
LFVN
LifeVantage Corp
53.14M
PRGO logo
PRGO
Perrigo Company PLC
1.49B
YCBD logo
YCBD
cbdMD Inc
7.14M
INM logo
INM
InMed Pharmaceuticals Inc
2.37M
Pattern Detection
Intellectia · 19 candidates
New High Low: 52w_High, 52w_Low, 20_High, 20_Low, 5_High, 5_LowList Exchange: XNASGap Pattern: GapUp, GapDownMoving Average Relationship: PriceCrossAboveMA5, PriceCrossAboveMA20, PriceCrossAboveMA200, PriceCrossDownMA5, PriceCrossDownMA20, PriceCrossDownMA200, PriceAboveMA5, PriceAboveMA20, PriceAboveMA200, PriceBelowMA5, PriceBelowMA20, PriceBelowMA200Candlestick Pattern: DescendingTriangle, AscendingTriangle, HeadAndShoulder, InverseHeadAndShoulder, WhiteCandlestick, BlackCandlestick, UpperShadow, LowerShadowSupport Resistance Relationship: PriceBreakResistance, PriceFallBelowSupport, PriceAroundResistance, PriceAroundSupport, PriceBreakUpperBoll, PriceFallBelowLowerBoll, PriceAroundUpperBoll, PriceAroundLowerBoll
Ticker
Name
Market Cap$
top bottom
WILC logo
WILC
G Willi Food International Ltd
399.80M
RDWR logo
RDWR
Radware Ltd
988.71M
MFI logo
MFI
mF International Limited
715.01M
SAIH logo
SAIH
SAIHEAT Ltd
20.05M
ZBAI logo
ZBAI
ATIF Holdings Ltd
86.12M
AIRG logo
AIRG
Airgain Inc
75.54M
stocks that fell over 20% yesterday
Intellectia · 19 candidates
Price Change Pct: $-100.00 - $-20.00
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
890.11K
IOBT logo
IOBT
IO Biotech Inc
14.94M
VERO logo
VERO
Venus Concept Inc
3.51M
IBG logo
IBG
Innovation Beverage Group Ltd
3.33M
JFBR logo
JFBR
Jeffs Brands Ltd
2.33M
SURG logo
SURG
Surgepays Inc
25.72M

Whales Holding INBS

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Intelligent Bio Solutions Inc (INBS) stock price today?

The current price of INBS is 2.29 USD — it has increased 1.78

What is Intelligent Bio Solutions Inc (INBS)'s business?

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes.

What is the price predicton of INBS Stock?

Wall Street analysts forecast INBS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Intelligent Bio Solutions Inc (INBS)'s revenue for the last quarter?

Intelligent Bio Solutions Inc revenue for the last quarter amounts to 1.06M USD, increased 45.54

What is Intelligent Bio Solutions Inc (INBS)'s earnings per share (EPS) for the last quarter?

Intelligent Bio Solutions Inc. EPS for the last quarter amounts to -1.80 USD, decreased -59.18

How many employees does Intelligent Bio Solutions Inc (INBS). have?

Intelligent Bio Solutions Inc (INBS) has 16 emplpoyees as of June 20 2026.

What is Intelligent Bio Solutions Inc (INBS) market cap?

Today INBS has the market capitalization of 5.48M USD.